CR11763A - Conjugados de factor ix con vidas medias extendidas - Google Patents

Conjugados de factor ix con vidas medias extendidas

Info

Publication number
CR11763A
CR11763A CR11763A CR11763A CR11763A CR 11763 A CR11763 A CR 11763A CR 11763 A CR11763 A CR 11763A CR 11763 A CR11763 A CR 11763A CR 11763 A CR11763 A CR 11763A
Authority
CR
Costa Rica
Prior art keywords
factor
conjugates
lives
extended medium
extended
Prior art date
Application number
CR11763A
Other languages
English (en)
Spanish (es)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of CR11763A publication Critical patent/CR11763A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CR11763A 2008-04-24 2010-10-27 Conjugados de factor ix con vidas medias extendidas CR11763A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4754408P 2008-04-24 2008-04-24

Publications (1)

Publication Number Publication Date
CR11763A true CR11763A (es) 2011-04-26

Family

ID=41171051

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11763A CR11763A (es) 2008-04-24 2010-10-27 Conjugados de factor ix con vidas medias extendidas

Country Status (22)

Country Link
US (1) US20110183906A1 (https=)
EP (1) EP2280734B1 (https=)
JP (1) JP2011519833A (https=)
KR (1) KR20110016440A (https=)
CN (1) CN102046205A (https=)
AU (1) AU2009239641B2 (https=)
BR (1) BRPI0911350A2 (https=)
CA (1) CA2722169A1 (https=)
CO (1) CO6300965A2 (https=)
CR (1) CR11763A (https=)
DK (1) DK2280734T3 (https=)
EC (1) ECSP10010632A (https=)
ES (1) ES2466340T3 (https=)
IL (1) IL208908A0 (https=)
MX (1) MX2010011672A (https=)
MY (1) MY158228A (https=)
NI (1) NI201000177A (https=)
NZ (1) NZ588854A (https=)
RU (1) RU2496521C2 (https=)
UA (1) UA101497C2 (https=)
WO (1) WO2009130602A2 (https=)
ZA (1) ZA201007559B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
CN102497884A (zh) 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
KR101912335B1 (ko) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN106110311A (zh) 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR20120061898A (ko) * 2009-08-20 2012-06-13 체에스엘 베링 게엠베하 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
UA126265C2 (uk) * 2010-07-09 2022-09-14 Байовератів Терапьютікс Інк. Поліпептид фактора іх і спосіб його застосування
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
EP3808378A1 (en) * 2011-05-27 2021-04-21 Baxalta GmbH Therapeutic proteins with increased half-life and methods of preparing same
MY190257A (en) * 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
MX2014015682A (es) * 2012-06-19 2015-07-23 Polytherics Ltd Proceso novedoso para preparacion de conjugados de anticuerpo y conjugados de anticuerpo novedosos.
TWI750197B (zh) 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Fix多肽的應用
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
EA202092926A3 (ru) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
GB2564389A (en) 2017-07-04 2019-01-16 Green Running Ltd A system and method for utility management

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
DE60138364D1 (de) * 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1578841B2 (en) * 2002-12-31 2016-10-12 Nektar Therapeutics AL, Corporation Maleamic acid polymer derivatives and their bioconjugates
WO2004060965A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP1581582B2 (en) * 2003-01-06 2017-06-07 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
WO2005033140A1 (ja) * 2003-09-30 2005-04-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 高純度血液凝固ix因子調製物およびその精製方法
ATE466074T1 (de) 2003-10-14 2010-05-15 Baxter Int Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR101146160B1 (ko) * 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ix 부분의 접합체
EP1819829A1 (en) 2004-12-08 2007-08-22 ICOS Corporation Recombinant method for making multimeric proteins
ES2397530T3 (es) 2005-02-28 2013-03-07 Baxter International Inc. Coexpresión recombinante de la subunidad 1 de la epóxido reductasa de la vitamina K para mejorar la expresión de proteína dependiente de la vitamina K
AU2005329450A1 (en) 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active Vitamin K-dependent proteins
EP1891231A4 (en) * 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
KR20090013816A (ko) * 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
JP5737821B2 (ja) * 2006-08-17 2015-06-17 一夫 大橋 血友病b治療剤及びその製造方法

Also Published As

Publication number Publication date
ES2466340T3 (es) 2014-06-10
KR20110016440A (ko) 2011-02-17
RU2010147813A (ru) 2012-05-27
CA2722169A1 (en) 2009-10-29
US20110183906A1 (en) 2011-07-28
IL208908A0 (en) 2011-01-31
AU2009239641A1 (en) 2009-10-29
BRPI0911350A2 (pt) 2017-12-05
EP2280734B1 (en) 2014-02-26
MX2010011672A (es) 2011-03-02
ZA201007559B (en) 2012-01-25
WO2009130602A2 (en) 2009-10-29
NI201000177A (es) 2011-08-29
AU2009239641B2 (en) 2013-11-07
CO6300965A2 (es) 2011-07-21
HK1151986A1 (en) 2012-02-17
EP2280734A2 (en) 2011-02-09
ECSP10010632A (es) 2011-02-28
UA101497C2 (ru) 2013-04-10
WO2009130602A3 (en) 2010-02-11
RU2496521C2 (ru) 2013-10-27
MY158228A (en) 2016-09-15
DK2280734T3 (da) 2014-05-26
NZ588854A (en) 2011-12-22
WO2009130602A9 (en) 2010-04-22
CN102046205A (zh) 2011-05-04
JP2011519833A (ja) 2011-07-14

Similar Documents

Publication Publication Date Title
CR11763A (es) Conjugados de factor ix con vidas medias extendidas
CU20110109A7 (es) Nueva composición a base de ácido gamma-hidroxibutírico
CR20110002S (es) Barra de chocolate
CO6400230A2 (es) Conjugados de insulina cristalina
CR20130337A (es) Amida aminoindanes con una alta actividad fungicida y sus composiciones fito sanitarias
EP2280053A4 (en) CIRCULAR POLARIZED LIGHT EMITTING NANOPARTICLES
EP2458654A4 (en) LIGHT-EMITTING DIODE
EP2329002A4 (en) CONCENTRATED HYDROGEN PEROXIDE DISINFECTION SOLUTIONS
MX2011011858A (es) Composiciones borinicas.
HN2008001466A (es) Forma galenica divisible que permite una liberacion modificada del principio activo
HN2009000017A (es) K i w i
HN2010000066S1 (es) Botella
DOP2011000393A (es) Derivados de pirazinooxazepina
AR058057A1 (es) Composicion de estabilidad aumentada y un procedimiento para preparar una composicion de este tipo
GB2476926B (en) Tuneable quantum light source
BR112012026157A2 (pt) processo para preparar ditiina-tetracarboximidas.
HN2009003469A (es) Biscocho lleno
EP1864330A4 (en) LIGHT AS A REPLACEMENT FOR MITROGENIC FACTORS IN CREATION CELLS
AR078548A1 (es) Composicion tonalizadora
FR2945103B3 (fr) Plaque lumineuse a del fine
HN2010002052S1 (es) Blanco para una llave
FR2944579B1 (fr) Support de source lumineuse du type diode electroluminescente.
UY33560A (es) Compuestos heterociclicos
ES2404379R1 (es) Elemento de soporte para un aparato doméstico, disposición con un elemento de soporte de tal tipo, y aparato doméstico con una disposición correspondiente
ES1070779Y (es) Fuente ornamental con proyector luminoso integrado

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)